Vectors Research Management’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Vectors Research Management’s Portfolio VCNX Stock Details VCNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-48	Closed	-$4K	–	141
2023 Q2	$4K	Buy	+48	New	+$3.99K	﹤0.01%	137
2023 Q1	–	Sell	-48	Closed	-$6K	–	141
2022 Q4	$6K	Hold	48	–	–	﹤0.01%	134
2022 Q3	$5K	Hold	48	–	–	﹤0.01%	135
2022 Q2	$11K	Hold	48	–	–	﹤0.01%	358
2022 Q1	$13K	Buy	48 +24	+100%	+$6.63K	﹤0.01%	329
2021 Q4	$5K	Hold	24	–	–	﹤0.01%	516
2021 Q3	$11K	Hold	24	–	–	﹤0.01%	359
2021 Q2	$14K	Hold	24	–	–	﹤0.01%	350
2021 Q1	$15K	Hold	24	–	–	﹤0.01%	307
2020 Q4	$10K	Hold	24	–	–	﹤0.01%	333
2020 Q3	$9K	Buy	+24	New	+$26.2K	﹤0.01%	308

Other funds holding VCNX

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tacita Capital Toronto, Ontario, Canada $184M AUM 26.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vectors Research Management's VCNX Position: Q3 2023 in Review

Vectors Research Management sold out of Vaccinex, Inc. Common Stock (VCNX) in Q3 2023, closing a stake of 48 shares — an estimated $4K sold.

Vectors Research Management first reported a position in VCNX in Q3 2020 and held it in 11 quarters. The position peaked at $15K in Q1 2021. 18 funds tracked by Wall St. Rank hold VCNX as of Q3 2023.

Vectors Research Management reported no remaining Vaccinex, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vectors Research Management sold 48 Vaccinex, Inc. Common Stock shares in Q3 2023, an estimated $4K.
Vectors Research Management first reported a position in Vaccinex, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Vectors Research Management's Vaccinex, Inc. Common Stock position peaked at $15K in Q1 2021.
18 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q3 2023.

Based on Vectors Research Management's 13F filing for Q3 2023, filed 9 Nov 2023.